Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-18-000563
Filing Date
2018-02-13
Accepted
2018-02-13 16:31:13
Documents
5

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO THE SCHEDULE 13D sc13da209271023_02132018.htm SC 13D/A 380164
2 SETTLEMENT AGREEMENT ex991to13da209271023_021318.htm EX-99.1 94372
3 GRAPHIC image_001.jpg GRAPHIC 2671
4 GRAPHIC image_003.jpg GRAPHIC 8174
5 GRAPHIC image_007.jpg GRAPHIC 6214
  Complete submission text file 0000921895-18-000563.txt   500336
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13D/A | Act: 34 | File No.: 005-31596 | Film No.: 18603895
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 13100 GREGG STREET SUITE A POWAY CA 92064
Business Address 1048 INDUSTRIAL COURT SUWANEE GA 30024 (858) 726-1600
DIGIRAD CORP (Filed by) CIK: 0000707388 (see all company filings)

EIN.: 330145723 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 3845 Electromedical & Electrotherapeutic Apparatus